NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) released its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01), FiscalAI reports. The company had revenue of $0.52 million during the quarter.

NovaBay Pharmaceuticals Stock Down 0.9%

Shares of NBY traded down $0.01 during mid-day trading on Friday, hitting $1.06. 163,616 shares of the company’s stock were exchanged, compared to its average volume of 2,185,460. The stock has a market cap of $6.37 million, a price-to-earnings ratio of -0.11 and a beta of 0.62. The firm has a fifty day moving average of $1.72 and a two-hundred day moving average of $1.02. NovaBay Pharmaceuticals has a twelve month low of $0.46 and a twelve month high of $4.44.

NovaBay Pharmaceuticals Announces Dividend

The firm also recently declared a dividend, which was paid on Monday, September 29th. Stockholders of record on Wednesday, October 1st were paid a dividend of $0.80 per share. The ex-dividend date was Tuesday, September 30th. This represents a dividend yield of 3,791.0%.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.